BAC
Bank of America Corporation
BAC has the edge over BCSF overall, supported by stronger valuation and stronger fundamentals.
BCSF
Bain Capital Specialty Finance, Inc.
BCSF trails on the overall score without a compensating advantage in the available component scores.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
BCSF Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| N/A | |
| N/A |
BCSF's profitability is currently healthy, but its revenue is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like BCSF.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over BCSF in the historical PE scenario, which offers more potential upside but is not a forecast.
BCSF PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.3x | $7.02 | -37% |
| Forward | 8.1x | $11.06 | — |
| Fair | 8.5x | $8.15 | -26% |
| Expensive | 10x | $9.56 | -14% |
| Current | 12x | $11.06 | — |
Historical ranges are pointers, not guarantees.
BCSF's PE is in its expensive range at 12x. On analysts' estimates for next year's earnings, today's price would be 8.1x, in its cheap range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over BCSF on the outlook, with more favorable earnings and revenue expectations.
BCSF Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect BCSF's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over BCSF on earnings, with more consistent year-over-year improvement.
BCSF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.37 | +43% |
| Q3 2026 | $0.96 | -33% |
| Q2 2026 | $0.99 | -40% |
| Q1 2026 | $1.14 | -34% |
| Q4 2025 | $1.53 | -17% |
| Q3 2025 | $1.44 | -28% |
| Q2 2025 | $1.66 | -17% |
| Q1 2025 | $1.74 | -13% |
| Q4 2024 | $1.85 | -2.6% |
BCSF's earnings per share have fallen from their peak: $0.96 over the past year, against $2.56 in mid-2021.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the stronger quarterly revenue trend. Revenue is up 6.7% for BAC versus down 40% for BCSF.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
BCSF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $30.4M | -40% |
| Q1 2022 | $46.3M | +5.3% |
| Q4 2021 | $40.7M | -22% |
| Q3 2021 | $40.4M | -41% |
| Q2 2021 | $50.3M | +23% |
| Q4 2020 | $52.5M | +27% |
BCSF's revenue has slid since its 2020 peak: $30M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | 57% | -28 points |
| Q1 2022 | 73% | +0.5 points |
| Q4 2021 | 55% | -21 points |
| Q3 2021 | 58% | -18 points |
| Q2 2021 | 84% | +31 points |
| Q1 2021 | 72% | N/A |
| Q4 2020 | 76% | +24 points |
| Q3 2020 | 76% | N/A |
BCSF's operating margin was 57% last quarter, down 28 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
BCSF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $137.9M | +1433% |
| Q2 2026 | $70.8M | +10858% |
| Q1 2026 | $26.6M | +$33.9M |
| Q4 2025 | $27.2M | +$47.1M |
| Q3 2025 | $9M | +$144.8M |
| Q2 2025 | $646K | -100% |
| Q1 2025 | -$7.3M | +$56.4M |
| Q4 2024 | -$20M | -107% |
BCSF has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over BCSF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
BCSF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
| 3 years | +0.5% | +306K shares |
| 5 years | +0.5% | +306K shares |
| Available history | +26% | +13.2M shares |
BCSF has 65M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
BCSF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 12.4x | High |
| Q1 2022 | 8.3x | High |
| Q4 2021 | 10.8x | High |
| Q3 2021 | 9.6x | High |
| Q2 2021 | 7.7x | High |
| Q1 2021 | 9.0x | High |
| Q4 2020 | 165.0x | High |
| Q4 2019 | 10.6x | High |
BCSF's net debt is about 12 years of its operating earnings (EBITDA), up from 7.7 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BCSF.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
BCSF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 31.3 | Neutral |
BCSF's weekly RSI is 41 (neutral) and its Stochastic is 31 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
BCSF PE vs Financial Services Sector
| Metric | BCSF | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 12% below |
| PE % | 93 | 63 | 30 pts above |
BCSF has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
BCSF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.8 | 2.8% above |
| 20 week MA | $11.7 | 5.1% below |
| 50 week MA | $12.6 | 12% below |
| 100 week MA | $14.2 | 22% below |
| 200 week MA | $14.7 | 25% below |
BCSF has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 25% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over BCSF on returns for 2026, with the stronger performance.
BCSF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.2 | $12.4 | -38% |
| 2021 | $12.4 | $15.6 | +25% |
| 2022 | $15.6 | $12.5 | -19% |
| 2023 | $12.5 | $15.1 | +20% |
| 2024 | $15.1 | $17.7 | +17% |
| 2025 | $17.7 | $13.9 | -21% |
| 2026 YTD | $13.9 | $11.1 | -21% |
BCSF has finished lower in three of the last six years. It's down 21% so far in 2026.